Health ministry recommends anti-malarial drug for COVID-19; removes anti-HIV drugs
New Delhi, Mar 31: The Union Health Ministry has recommended the use of anti-malarial drug hydroxychloroquine in combination with azithromycin on those severely suffering from COVID-19 who require ICU management.
In its revised guidelines on the 'Clinical Management of COVID-19' issued on Tuesday, the ministry said the drug is presently not recommended for children aged less than 12 and pregnant and lactating women.
"No specific antivirals have been proven to be effective as per currently available data. However, based on the available information (uncontrolled clinical trials), the following drugs may be considered as an off–label indication in patients with severe disease and requiring ICU management," the ministry said while recommending the drug combination.
The ministry has removed its earlier recommendation of the use of anti-HIV drug combinations Lopinavir and Ritonavir on a case-to-case basis depending upon the severity of the condition of a patient suffering from coronavirus infection.
"As per latest clinical data available from across the work, Lopinavir and Ritonavir drug combination was not found to have significant benefit for patients of COVID-19 so it has been discontinued," a health ministry official said.
This document is intended for clinicians taking care of hospitalised adult and paediatric patients of COVID–19, the guidelines stated.
Best practices for COVID-19 including infection prevention and control (IPC) and optimized supportive care for severely ill patients are considered essential, it said, adding that the document aims to provide clinicians with updated interim guidance on timely, effective and safe supportive management of patients with COVID-19, particularly those who have severe acute respiratory illness and are critically ill.
The guidelines issued by the health ministry also state that COVID-19 patients may have mild, moderate, or severe illness -- the latter includes severe pneumonia, acute respiratory distress syndrome (ARDS), sepsis and septic shock.
"Early identification of those with severe manifestations allows for immediate optimised supportive care treatments and safe, rapid admission (or referral) to intensive care unit according to national protocols," the document states.
The guidelines advise the treating doctors to closely monitor patients with severe acute respiratory infection for signs of clinical deterioration, such as rapidly progressive respiratory failure and sepsis, and apply supportive care interventions immediately.
"Application of timely, effective, and safe supportive therapies is the cornerstone of therapy for patients who develop severe manifestations of COVID-19," it said.
"Understand the patient's co-morbid condition to tailor the management of critical illness and appreciate the prognosis. During intensive care management of severe acute respiratory infection, determine which chronic therapies should be continued and which therapies should be stopped temporarily."
The guidelines also recommend that the patients and their families must be communicated with pro-actively and provided support and prognostic information. They also recommend to medical practitioners to understand the patient's "values and preferences" regarding life-sustaining interventions.